Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Aditxt Inc is a biotechnology business based in the US. Aditxt shares (ADTX) are listed on the NASDAQ and all prices are listed in US Dollars. Aditxt employs 43 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.45 |
|---|---|
| 52-week range | $0.35 - $5.59 |
| 50-day moving average | $0.76 |
| 200-day moving average | $1.87 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.86 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.4549 from 2022-01-25
| 1 week (2022-01-15) | N/A |
|---|---|
| 1 month (2021-12-23) | -35.94% |
| 3 months (2021-10-22) | N/A |
| 6 months (2021-07-26) | -80.64% |
| 1 year (2021-01-26) | -86.97% |
|---|---|
| 2 years (2020-01-22) | N/A |
| 3 years (2019-01-22) | N/A |
| 5 years (2017-01-22) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -80.87% |
| Return on equity TTM | -202.1% |
| Profit margin | 0% |
| Book value | $0.54 |
| Market capitalisation | $17.8 million |
TTM: trailing 12 months
We're not expecting Aditxt to pay a dividend over the next 12 months.
Aditxt, Inc. , a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.